Wellthy Therapeutics
Pioneering Digital Therapeutics for Chronic Disease management in Asia and EM #Diabetes #Hypertension #Dyslipidemia.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2023 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 21 % | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Wellthy Therapeutics is a digital therapeutics company focused on improving patient outcomes through the use of artificial intelligence and patient-centric design. The company primarily serves individuals with chronic diseases, such as type 2 diabetes, and operates in the digital health market. Wellthy Therapeutics partners with healthcare stakeholders, including doctors and industry partners, to deliver its solutions. The business model revolves around deploying digital care platforms that facilitate behavior change, improve health literacy, and help manage chronic conditions. Revenue is generated through partnerships, licensing, and subscription models for its digital care solutions. Keywords: digital therapeutics, AI, chronic disease, patient outcomes, health equity, type 2 diabetes, behavior change, health literacy, digital health, partnerships.